clinical trial · NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMixed Phenotype Acute LeukemiaAcute Undifferentiated LeukemiaChronic Myeloid Leukemia in Myeloid Blast CrisisChronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)Chronic Myeloid Leukemia - Accelerated PhaseOrca-Q
brief summary
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
started
Aug 16, 2022
primary completion
Sep 1, 2026
completion
Sep 1, 2027
last updated
Apr 13, 2026
official title
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol